SNNAQ — Sienna Biopharmaceuticals Share Price
Last trade - 00:00- $0.00m
- -$11.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -121.74% | ||
| Return on Equity | -140.97% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2014 | 2015 | 2016 | 2017 | 2018 | 2019E | 2020E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on bringing scientific innovations to patients whose lives remain burdened by their disease. Its lead candidate from its platform, SNA-120, is an inhibitor of Tropomyosin receptor kinase A (TrkA) for the treatment of psoriasis, as well as the associated pruritus (itch). The Company's second product candidate, SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for the treatment of atopic dermatitis, psoriasis and the associated pruritus. In addition, the Company also offers SNA-001, a silver photo particle technology derived from its Topical Photoparticle Therapy platform.
Directors
- Keith Leonard CHM (59)
- Frederick Beddingfield PRE (52)
- Alexander Azoy CFO (44)
- Sean Andrews VPR
- Timothy Andrews GCN (42)
- Kristina Burow DRC (47)
- Dennis Fenton DRC (68)
- Todd Harris DRC (40)
- James Hindman DRC (60)
- Robert More DRC
- Last Annual
- December 31st, 2018
- Last Interim
- September 30th, 2019
- Incorporated
- July 27th, 2010
- Public Since
- July 27th, 2017
- No. of Shareholders
- 91
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 30,907,542
- Address
- 30699 Russell Ranch Rd Ste 140, WESTLAKE VILLAGE, 91362-7327
- Web
- https://siennabio.com/
- Phone
- +1 8186292256
- Auditors
- Ernst & Young LLP
Upcoming Events for SNNAQ
Similar to SNNAQ
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:19 UTC, shares in Sienna Biopharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Sienna Biopharmaceuticals last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Sienna Biopharmaceuticals share price has underperformed the S&P500 Index by -11.77% over the past year.
The overall consensus recommendation for Sienna Biopharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Sienna Biopharmaceuticals does not currently pay a dividend.
Sienna Biopharmaceuticals does not currently pay a dividend.
Sienna Biopharmaceuticals does not currently pay a dividend.
To buy shares in Sienna Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Sienna Biopharmaceuticals had a market capitalisation of $0.00m.
Here are the trading details for Sienna Biopharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SNNAQ
Based on an overall assessment of its quality, value and momentum Sienna Biopharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sienna Biopharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -99.14%.
As of the last closing price of $0.00, shares in Sienna Biopharmaceuticals were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sienna Biopharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sienna Biopharmaceuticals' management team is headed by:
- Keith Leonard - CHM
- Frederick Beddingfield - PRE
- Alexander Azoy - CFO
- Sean Andrews - VPR
- Timothy Andrews - GCN
- Kristina Burow - DRC
- Dennis Fenton - DRC
- Todd Harris - DRC
- James Hindman - DRC
- Robert More - DRC